CareDx Inc. must pay Natera Inc. $96.3 million after a federal jury in Delaware found two of its DNA-based tests infringe patented technology for detecting organ-transplant rejections.
Jurors determined CareDx’s AlloSure test and its AlloSeq, used to identify the best donor match, infringe one of two patents related to the cell-free DNA tests, according to the verdict issued Jan. 26 for the trial’s liability phase in the US District Court for the District of Delaware.
The jury’s verdict in the trial’s damages phase awarded $83.7 million in lost profits for infringing sales of AlloSure, a royalty of $12.5 million for ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.